CTOs on the Move

Onconano Medicine

www.onconanomed.com

 
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Onconano Medicine raised $11.7M on 05/17/2018
Onconano Medicine raised $22M on 04/24/2019
Onconano Medicine raised $23.7M on 09/04/2019
Onconano Medicine raised $15.4M on 08/27/2019

Similar Companies

Exagen Diagnostics

Exagen Diagnostics, Inc. is committed to providing excellent service to our physicians, patients and partners.

Synlogic

Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.

Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient`s unique cancer. The company`s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient`s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine`s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

Celmatix

Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.

Tripos

Tripos, L.P. is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.